CEO and director buy shares.
David Ricks, CEO and President of Eli Lilly and Company (LLY), recently picked up 4,615 shares. At a cost of $500,000, the buy increased his stake by nearly 3 percent.
On the same day, Director Jackson Tai bought 1,861 shares at a slightly lower price, shelling out $200,000 in total. These buys are the first following a series of sales in September by a number of officers and an endowment that is also a major holder of shares.
- 25-Year-Old Prodigy Reveals Secret to Soaring Stocks
“Old school” folks might be skeptical of listening to financial advice from someone half their age, but this stock whiz beat out 15,000 experts to claim #1 title.
Eli Lilly is a developer and manufacturer of pharmaceutical products worldwide, with various products and vaccines for human and animal use. As part of the out-of-favor healthcare sector where insiders keep buying, shares have lagged the S&P 500 by 12 points in the past year.
Action to take: With shares trading at 17 times forward earnings, they’re a bit cheaper than the overall market even as the share price has moved higher in recent months. With 9 percent earnings growth in the past year, it’s definitely more of a value play, but the company has fat 31 percent profit margins and is likely to continue to deliver for investors. Shares look attractive up to $115.00.
Traders may want to consider the January 2021 $115 calls, which currently trade for around $10.00, or $1,000 per contract. It’s a leveraged way to control 100 shares, and are near-the-money. A move to the old 52-week high of $132 would increase these options by 70 percent to $17 at expiration.